We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | NYSE:LLY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 13.51 | 1.75% | 783.51 | 784.325 | 766.12 | 766.90 | 2,188,712 | 00:41:55 |
From May 2019 to May 2024
By Josh Beckerman
Eli Lilly & Co.'s (LLY) Type 2 diabetes drug Trulicity has been approved by the U.S. Food and Drug Administration, the agency said Thursday.
The drug is a subcutaneous injection that helps improve blood sugar levels.
The FDA is requiring certain postmarketing studies for Trulicity.
Write to Josh Beckerman at josh.beckerman@wsj.com
Access Investor Kit for Eli Lilly & Co.
Visit http://www.companyspotlight.com/partner?cp_code=A591&isin=US5324571083
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Eli Lilly Chart |
1 Month Eli Lilly Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
